pression of p16 protein and any of the clinicopathological parameters. However, there was a tendency for the tumor to be larger in patients with decreased expression of p16 protein than in those with normal expression levels. In contrast, the tumor was significantly larger and the survival period significantly shorter for patients with pancreatic carcinoma with p16 mutation or hypermethylation than for those with pancreatic carcinoma with an intact p16 gene (P Ͻ 0.05). Conclusions. These findings suggest that p16 alterations may participate in the aggressiveness of pancreatic carcinoma.
Introduction
The carcinogenesis and progression of pancreatic carcinoma (PC) have been elucidated and various carcinoma-related genes reported in PC. For example, a K-ras mutation at codon 12 has been found in 75%-100%, and a p53 mutation has been recognized in 40%-76% of PC tissues. [1] [2] [3] [4] [5] [6] To date, we have reported mutations of K-ras and p53 in pure pancreatic juice and duodenal juice for application to clinical practice. [7] [8] [9] [10] [11] [12] [13] The cell cycle is regulated by cyclin and cyclindependent kinase (CDK). 14, 15 CDKs in turn are negatively regulated by cyclin-dependent kinase inhibitors (CDKIs). 16, 17 The p16 gene is the most important inhibitor of CDKIs. The p16 protein was identified in 1993 by Serrano et al. 18 Soon afterward, MTS1 (multiple tumor suppressor gene 1) was found to be a tumor suppressor gene, coding the p16 protein, in 9p21 by Kamb et al. 19 and Nobori et al. 20 Although a high incidence of p16 abnormalities has been reported in various human tumors [21] [22] [23] [24] [25] [26] [27] and in pancreatic cell lines and xenografts, 1, [28] [29] [30] such abnormalities are relatively rare in primary PC Background. Abnormalities of the tumor suppressor gene p16 have been reported in a variety of human tumors but are rare in pancreatic carcinoma except for cancer cell lines and xenografts. Their clinicopathological significance remains unknown. The purpose of this study was to examine immunohistochemical and genetic alterations of p16 in primary pancreatic carcinoma tissues and to investigate the relation between abnormalities of p16 and clinicopathological parameters to elucidate their clinicopathological significance. Methods. We investigated p16 expression in 60 pancreatic carcinoma cases by immunohistochemistry using a monoclonal antibody clone G175-405. In addition, we analyzed genetic alterations of the p16 gene using DNA extracted from microdissected tissue of pancreatic carcinoma, by polymerase chain reaction, nonradioisotopic single-strand conformation polymorphism (non-RI-SSCP), DNA sequencing, and hypermethylation analyses using restriction enzymes. We compared the abnormalities of p16 alterations with clinicopathological parameters to elucidate their significance. Results. On immunohistochemical study, staining for p16 protein was strongly positive in 22 (37%) of 60 pancreatic carcinoma cases, weakly positive in 24 (40%), and negative in 14 (23%). In contrast, p16 mutations were recognized in 9 (15%) of the 60 pancreatic carcinoma cases. The incidence of p16 mutations was 2 (9%) in 22 cases of pancreatic carcinoma with strongly positive staining, 4 (17%) in 24 with weakly positive staining, and 3 (21%) in 14 with negative staining. Hypermethylation of p16 was detected in the two pancreatic carcinoma cases with weakly positive staining, although homozygous deletions were not found in any case. There was no significant correlation between the ex-tissues. [31] [32] [33] [34] In addition, there have been no reports of comparisons between the immunohistochemistry and genetic alterations or between the abnormalities of p16 and clinicopathological parameters in primary PC tissues. Therefore, the clinicopathological significance of p16 in PC remains unknown.
The purpose of this study was to examine immunohistochemical and genetic alterations of p16 in primary PC tissues and to investigate the relation between abnormalities of p16 and clinicopathological parameters to elucidate their clinicopathological significance.
Materials and methods

Pancreatic carcinoma tissues
We studied 60 cases of PC resected at surgery (including two autopsy cases) and confirmed pathologically in Kanazawa University Cancer Research Institute Hospital and affiliated hospitals from January 1987 to March 2000. Informed consent was obtained from all patients (32 men, 28 women). Their ages ranged from 42 to 89 years (average 66.7 years). Tumor size was classified according to the criteria used by the Japan Pancreas Society. 35 A total of 7 PCs were classified as tumor size 1 (TS1) (greatest dimension Յ 2 cm), 31 as TS2 (Ͼ2 cm but Յ 4 cm greatest dimension), 13 as TS3 (Ͼ4 cm but Յ 6 cm greatest dimension), 6 as TS4 (Ͼ6 cm greatest dimension), and 3 as unknown. Altogether, 40 tumors were from the head, 12 from the body, and 7 from the tail of the pancreas; 1 was of unknown origin. The pathology of PC tissues was diagnosed as papillary adenocarcinoma in 4 cases, well-differentiated adenocarcinoma in 17 cases, moderately differentiated adenocarcinoma in 26 cases, poorly differentiated adenocarcinoma in 10 cases, adenosquamous carcinoma in 2 cases, and unknown in 1 case. The staging of the PC was done according to the TNM classification as set down by the International Union Against Cancer 36 ; it was judged to be stage I for 12 patients, stage II for 10 patients, stage III for 25 patients, stage IV for 12 patients, and unknown in 1 case. Lymph node and distant metastases were identified in 24 and 10 of 60 PC cases, respectively.
All PC tissues were fixed in formalin and embedded in paraffin. Sections were cut 3-4 µm thick for immunohistochemistry and 8-10 µm thick for genetic analysis of p16.
Immunohistochemical staining of p16
Immunohistochemical staining of p16 was performed according to the method of Hu et al. 37 Immunoreactivity was regarded as positive when the nuclei of more than 5% of target cells were stained regardless of cytoplasmic staining. Surrounding stromal cells, such as lymphoid cells and acinar cells, were used as an internal control. Immunostaining as intense as the internal control was considered strongly positive. Less intense immunostaining was regarded as weakly positive. 38 A negative or weakly positive immunoreaction was considered abnormal.
DNA extraction
Tumor sections were deparaffinized with xylene and ethanol and then microdissected to enrich for neoplastic tissues prior to DNA isolation. DNA was extracted with a phenol-chloroform mixture and precipitated with ethanol according to the method of Goelz et al. 39 
Non-RI-SSCP analysis
For the nonradioisotopic single-strand conformation polymorphism (non-RI-SSCP) analysis we used primers of exons 1 and 2 of p16 according to Hussussian et al. (exon 1) 40 and Okajima et al. (exon 2). 41 Exon 2 of p16 was divided into two fragments: 2A (5Ј fragment) and 2B (3Ј fragment). The sequences of primers were as follows: exon 1 sense, 5Ј-GGGAGCAGCATGGAGC CG-3Ј; exon 1 antisense, 5Ј-AGTCGCCCGCCATCC CCT-3Ј; exon 2A sense, 5Ј-TCTCTCTGGCAGGTCA TGAT-3Ј; exon 2A antisense, 5Ј-AGCACCACCAG CGTGTCCAG-3Ј; exon 2B sense, 5Ј-TTCCTGGAC ACGCTGGTGGT-3Ј; exon 2B antisense, 5Ј-GATC ATCAGTCCTCACCTGA-3Ј. The size of the polymerase chain reaction (PCR) products was 204 bp for exon 1, 132 bp for exon 2A, and 206 bp for exon 2B. The PCR mixture was composed of template DNA (100 ng), 10 ϫ PCR buffer 2 µl (Perkin-Elmer Cetus, Foster, CA, USA), dNTPs 4 pmol (Takara, Kyoto, Japan), AmpliTaq DNA polymerase 1 U (Perkin-Elmer Cetus), and primer mixture 10 pmol for exon 2A. For exons 1 and 2B, we used 2 µl 2 ϫ GC buffer I (Takara) and 1 U TaKaRa LA Taq (Takara) instead of 10 ϫ PCR buffer and AmpliTaq DNA polymerase, respectively. Then water was added to a total volume of 20 µl. PCR was performed using TaKaRa MP MT3000 (Takara) with denaturing at 95°C for 1 min, annealing at 62°C (exons 1 and 2A) or 60°C (exon 2B) for 1 min, and extension at 72°C for 1 min, for 40 cycles, and a final extension at 72°C for 6 min. PCR products were electrophoresed using 2% NuSieve 3 : 1 agarose gel (FMC BioProducts, Rockland, ME, USA) and stained with SyBr Green I (Nippon Gene, Tokyo, Japan). After sample denaturation with 95% formamide for 5 min at 95°C, electrophoresis was performed at 4°C and 150 V for 6-24 h (exon 1, 24 h; exon 2A, 6-12 h; exon 2B, 18 h) using 15% homogeneous polyacrylamide gel with a buffer circulat-ing thermocontrol system (ATTO, Tokyo, Japan), followed by staining with SyBr Green II (Nippon Gene). Additional bands that shifted differently from the wildtype bands were judged abnormal. 42 For imaging analysis, densitograph systems and software (ATTO) were used. The abnormal bands were cut from the gel, and DNA was extracted from them. The DNA was used as the template for the second PCR. Second PCR products obtained under the same conditions were purified with SUPPEC-02 (Takara) and used as the template for sequence analysis.
Sequencing analysis
For the cycle sequence reaction, the PCR mixture was made with Big Dye Terminator Cycle Sequence Reaction agent 8 µl (Perkin-Elmer Cetus), template DNA 100 ng, and primer mixture 10 pmol. Water was then added to a total volume of 20 µl. PCR was performed using TaKaRa MP MT3000 with denaturing at 96°C for 30 s, annealing at 50°C for 15 s, and extension at 60°C for 4 min, for 25 cycles. Reaction products were purified with a Centrisep spin column (Perkin-Elmer Cetus), and sequence analysis was performed with the ABI PRISM 310 Genetic Analyzer (PE Biosystems Japan, Chiba, Japan).
Hypermethylation analysis
The hypermethylation status of exon 1 of p16 was investigated according to the method of Gonzalez-Zulueta et al. 43 All the DNA (1 µg) samples were individually digested for 12 h with 10 units of methylation-sensitive (Sac II, Hpa II; Roche, Mannheim, Germany) and methylation-insensitive (Msp I; Roche) enzyme. We used undigested DNA as a positive control. The sequences of the primers were as follows 44 : sense, 5Ј-GGGAGCAGCATGGAGCCG-3Ј; antisense, 5Ј-CTG GATCGGCCTCCGACCGTA-3Ј. The PCR mixture was composed of template DNA (100 ng), 10 ϫ PCR buffer (1 µl), dNTPs (2 pmol), AmpliTaq DNA polymerase (0.5 U), and primer mixture (5 pmol). Water was then added to a total volume of 10 µl. PCR was performed using the TaKaRa MP MT3000 with denaturing at 95°C for 1 min, annealing at 62°C for 1 min, and extension at 72°C for 1 min, with a final extension at 72°C for 6 min. The optimal cycle number was determined as that giving a detectable band of minimal intensity from the undigested template DNA and no detectable signal from Msp I-digested DNA. PCR products were electophoresed using 2% NuSieve 3 : 1 agarose gel and stained with SyBr Green I. If PCR bands were obtained after treatment with methylation-sensitive but not methylation-insensitive enzymes, the case was determined to be positive for hypermethylation.
Clinicopathological findings
We classified 60 PC cases by tumor size, localization, histological grade, clinical stage, nodal metastasis, and distant metastasis. We then compared the expression of p16 protein as well as p16 genetic alterations with the clinicopathological parameters. Furthermore, we analyzed survival period in 38 patients with an intact p16 gene and 10 patents with a p16 mutation or hypermethylation. In this analysis, we eliminated the cases in which information about prognosis was not obtained.
Statistical analyses
The 2 test was used to compare data between two subgroups of patients classified based on the results of immunohistochemical and genetic abnormalities of p16. The prognosis of patients was evaluated by the KaplanMeier method. Uninformative cases were eliminated from this analysis. In addition, multivariate analyses were performed using the Cox hazard model. Probability values of Ͻ0.05 (two-tailed) were regarded as statistically significant.
Results
The intensity of the immunohistochemical staining for p16 protein was uniform in 57 cases. In the remaining 3 PC cases, we selected 1000 cells from the visual field and determined the immunoreactivity. According to the criteria, the expression of p16 protein was positive in 22 (37%), weakly positive in 24 (40%), and negative in 14 (23%) of the 60 PC cases (Fig. 1) .
We obtained PCR bands in exon 2A in all 60 cases. However, under the same PCR conditions, we observed PCR bands in exons 1 and 2B in only about half of the cases. Therefore, we used 2 ϫ GC buffer I and TaKaRa LA Taq to raise the amplification efficacy of the PCR products. Under these conditions, we obtained PCR bands in all but two cases in exon 1.
With non-RI-SSCP analysis, mutant bands were observed in nine cases (exon 1 in two cases and exon 2 in seven cases). In case 1 (Table 1) , mutant bands were recognized in both exon 2A and exon 2B. Sequencing analysis was performed for the mutant bands of the nine cases (total of 10 samples). The results were as follows: seven cases of missense mutation, two cases of silent mutation, and one case of frame shift mutation that produced a stop codon (TGA) (Table 1, Fig. 2) . Case 1 involved a missense mutation in exon 2A and a silent mutation in exon 2B. In case 9, the same silent mutation was detected in normal pancreatic tissue as well as in PC tissue. Therefore, we determined case 9 to be polymorphic. No hot spot of mutation was recognized except for codon 75, in which a missense mutation [conversion from CAC (His) to CCC (Pro)] was observed in two cases.
For the hypermethylation analysis, we examined 35 of the 60 cases (12 strongly positive, 16 weakly positive, 7 negative). In two cases with weakly positive immunostaining, we obtained a PCR band with or without digestion by Sac II and Hpa II but no PCR band after digestion by Map I. We considered these two cases positive for hypermethylation (Fig. 3) . In neither case was a mutation of p16 recognized by SSCP analysis. The other 33 cases were regarded as negative for hypermethylation because PCR bands were obtained only without a restriction enzyme.
Among 22 PC cases with normal immunohistochemical staining of p16 protein, only 2 showed a genetic alteration. In contrast, among 38 cases with abnormal p16 immunostaining, 9 showed genetic or epigenetic alterations (7 cases of mutation, 2 cases of hypermethylation). However, the difference between these two groups was not significant (P ϭ 0.23).
We compared the relation between the p16 abnormalities and various clinicopathological parameters. In the univariate analysis, there was no significant correlation between p16 expression and any clinicopathological parameter, although in the patients with decreased expression of p16 protein the tumor tended to be larger than in those with normal expression levels (P ϭ 0.081). In contrast, in the patients with a p16 mutation or hypermethylation, the tumor was significantly larger and the survival significantly shorter than for PC patients with an intact p16 gene (tumor size, P ϭ 0.049; survival period, P ϭ 0.022), although there was no correlation between a p16 mutation or hypermethylation and tumor location, histological grade, clinical stage, or lymph node or distant metastasis (Table 2) . With the Kaplan-Meier analysis, we analyzed the survival period in 38 patients with an intact p16 gene and 10 patients with a p16 mutation or hypermethylation. Although there was no significant correlation between p16 protein expression and prognosis, the survival period was significantly shorter for PC patients with a p16 mutation or hypermethylation than for those with an intact p16 gene (P ϭ 0.028) (Fig. 4) .
On the other hand, multivariate analysis revealed a significant correlation between poor prognosis and advanced clinical staging (P ϭ 0.0048) or lymph node metastasis (P ϭ 0.019) but not tumor size, tumor loca- tion, histological grade, distant metastasis, or p16 abnormalities.
Discussion
Abnormalities of the p16 gene have been reported in a variety of human malignancies. [21] [22] [23] [24] [25] [26] [27] The first report of p16 mutations in PC cell lines and xenografts by Caldas et al. 28 described homozygous deletions and mutations at 44% and 38%, respectively. Other studies using PC cell lines and xenografts 1, 29, 30 supported these results. However, genetic alterations are relatively rare in primary PCs. Bartsch et al. 31 and Huang et al. 32 reported that only 12 (37%) of 32 cases and 8 (27%) of 30 cases showed a homozygous deletion or somatic mutation in primary PC tissues, respectively. Table 1 ) Fig. 3 . Hypermethylation analyses using restriction enzymes. Left In the control, hypermethylation analysis showed a polymerase chain reaction (PCR) band only in the undigested enzyme (arrow). Right In case 10, with weakly positive staining for p16, the hypermethylation analysis gave a positive result because the same PCR bands were obtained with or without the digestion by Sac II and Hpa II, whereas no PCR band was obtained after digestion by Msp I (arrow). U, undigested; S, Sac II; H, Hpa II; M, Msp I
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In this study, we identified somatic mutations in 9 of 60 cases (15%). The frequency of mutation was higher in exon 2 than exon 1 (seven cases in exon 2 compared with two for exon 1). This result is consistent with previous reports. 21, 26, 31, 32, 45 In addition, a polymorphism was observed in exon 2. However, a homozygous deletion was not recognized in any of the 60 cases, possibly because of contamination by normal cells.
Much attention has recently been paid to the hypermethylation of a tumor suppressor gene as the epigenetic mechanism of transcriptional silencing. 46 This phenomenon induced genetic inactivation and carcinogenesis. 47 Hypermethylation of p16 has been reported in various human tumors. 33, 34, 38, 42, [48] [49] [50] [51] [52] [53] [54] In PC tissues, Sugimoto et al. 33 found that none of 24 cases showed hypermethylation using restriction enzymes. In contrast, hypermethylation could be identified in 5 (14%) of 36 PC tumors by Ueki et al. 34 and in 11 (28%) of 40 PC tumors by Gerdes et al. 45 using methylationspecific PCR (MSP). In the present study, we analyzed the status of hypermethylation with restriction enzymes. 44 We detected only 2 (6%) of 35 PC tissues with weakly positive immunostaining. MSP is more sensitive for detecting hypermethylation than the analysis with restriction enzymes. Hypermethylation of a single cell could be detected among 1000 normal cells by MSP. 48 Given the MSP is available in this study, the incidence of hypermethylation in PC cases may be found to be increased.
Gonzalez-Zulueta et al. 43 clearly showed that there was a highly significant correlation between the loss of p16 expression and hypermethylation of its promoter in bladder cancer but not a significant association between methylation of exon 2 and transcriptional repression of p16, indicating that methylation of exon 1, but not exon 2, of p16 is associated with transcriptional silencing. Also in the PC tumors, hypermethylation of the p16 promoter was found in 11 of 27 PC cases without p16 expression and not in any PC cases (n ϭ 13) with p16 expression. 45 We observed hypermethylation of the p16 promoter in only 2 of 23 PC patients with abnormal immunostaining of p16, but not at all in PC patients with normal immunostaining. Thus, it is presumed that the p16 gene is inactivated by hypermethylation of its promoter also in a considerable number of PC tumors, although the incidence of p16 hypermethylation was low in our study using restriction enzymes.
Previously we reported that 26 (42%) of 62 PC tissues lost p16 expression. 37 In that report, we classified the degree of immunohistochemical staining as positive or negative. In the present study, we classified staining as strongly positive, weakly positive, or negative. We classified strongly positive immunostaining as normal and weakly positive or negative staining as abnormal. The results of immunohistochemical staining of the p16 protein were 22 (37%) strongly positive cases, 24 (40%) weakly positive cases, and 14 (23%) negative cases among the 60 PCs. We determined that 38 (63%) of 60 PC patients had abnormal expression of p16 protein.
We detected 9 (24%) of 38 PC patients who harbored a mutation or hypermethylation with abnormal expression of p16 protein; there were only 2 (9%) of 22 PCs with normal expression. Genetic alterations of p16 tended to be detected more in patients with immunohistochemically p16-negative than p16-positive tumors. Gerdes et al. 45 reported that p16 alterations (mutation or hypermethylation) were recognized in 10 of 20 (50%) short-term survivors (median survival 6 months) and 6 of 20 (30%) long-term survivors (median survival 36 months), indicating that the presence of p16 alterations in PC patients is associated with a worse prognosis. Furthermore, they identified somatic mutations of p16 in 6 (15%) cases and hypermethylation in 11 (28%) of 40 PC tumors, respectively. The frequency of mutations found by them is identical with that of the present study (15%, 9/60 cases). However, the frequency of p16 hypermethylation in the former is higher than in the latter (28% vs 6%). This difference is thought to be due to the lower sensitivity of the restriction enzyme method we used for the analysis of p16 hypermethylation. We did not observe any mutations or hypermethylation in the remaining 29 cases with abnormal p16 expression, which might be due to undetected mutations or hypermethylation on the basis of limitations of PCR-SSCP for mutation analysis and the restriction enzyme method for hypermethylation analysis. More likely, the loss of p16 expression in these PC tumors could be caused by homozygous deletion, which could not be found chiefly due to insufficient elimination of normal cells. Gerdes et al. 45 also reported that mutation or hypermethylation was not recognized in any PC patients with positive immunostaining. However, one case with normal expression of p16 protein showed a missense mutation in the present study.
It is known from the literature that the genetic or epigenetic alterations of oncogenes are not always reflected in the abnormal expression of oncogene protein in cancer tissues. 55 We speculated that the reasons for this are as follows: First, the genetic or epigenetic variation may exist only in a part of the PC tumor; consequently, the expression of p16 protein does not decrease. Second, the conformational changes due to p16 mutation may not have influenced the epitope of the p16 antigen for the p16 antibody.
In neuroblastoma 56 and lung adenocarcinoma, 57 the expression of p16 is related to advanced clinical staging and a poor prognosis. Recently, Gerdes et al. 45 reported that the presence of p16 alterations in resected tumors of patients with PC is associated with a worse prognosis. We compared the relation between p16 abnormalities and various clinicopathological parameters. The univariate analysis showed that for PC patients with abnormal expression of p16 the tumor tended to be larger than those in PC patients with normal expression of p16, although a significant correlation was not recognized. In contrast, in those with a mutation or hypermethylation of p16, the PC was significantly larger and the survival period significantly shorter than for PC patients with an intact p16 gene. The Kaplan-Meier analysis showed that for PC patients with a mutation or hypermethylation of p16 there was a tendency for a poor prognosis (P ϭ 0.028). Our results are considered to be in line with the reports in the literature. 45, 56, 57 The K-ras mutation is thought to occur during the early stage of pancreatic carcinogenesis because it is observed in mucous cell hyperplasia, which is supposed to be a precancerous lesion. 58 On the other hand, p53 mutation is thought to occur during the late stages. 59, 60 Wilentz et al. 61 proposed a progression model for PC, where K-ras is mutated first, followed by p16, and finally p53 and DPC4. However, in our study p16 abnormalities were associated with a large tumor and short survival period and were thought to occur late in pancreatic carcinogenesis. In this regard, our results suggest that p16 may participate in the late events of pancreatic carcinogenesis.
In summary, we have reported the analysis of K-ras and p53 mutations in pancreatic juice for application to daily practice. [7] [8] [9] [10] [11] [12] [13] We also investigated mutations of p16 in pancreatic juice from several patients with PC. Among them, one patient showed a nonsense mutation (GAG (Gly)AETAG (stop codon)) in exon 2B (data not shown). From now on, we will evaluate the abnormalities of p16 in the pancreatic juice from many PC cases. The p16 abnormalities in pancreatic juice may become a marker for a poor prognosis in PC patients.
